Dateline City:
KENILWORTH, N.J.
New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer
First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers
Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new investigational data in 10 different types of
cancer from the companys immuno-oncology development program evaluating
its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), will be
presented at the 51st Annual Meeting of the American Society
of Clinical Oncology (ASCO) in Chicago, May 29 June 2, 2015.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more